Sirt 1 activator including syringaresinol

Patent metadata

Field	Value
Publication number	US-2016263079-A1
Application number	US-201615160239-A
Country	US
Kind code	A1
Filing date	May 20, 2016
Priority date	Oct 18, 2011
Publication date	Sep 15, 2016
Grant date	—

Abstract

The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

First claim

1 . A method of treating an eye disease in a subject suffering from the eye disease comprising administering an effective amount of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof to the subject:

wherein
R 1 , R 2 , R 3 or R 4 are independently an unbranched or branched C 1 -C 18 alkyl group, C 1 -C 18 alkoxy group, C 1 -C 18 alkenyl group, C 1 -C 18 alkynyl group or C 3 -C 6 cyclic alkyl group, and
R 5 , R 6 , R 7 , R 8 , R 9 , R 10 or R 11 are independently hydrogen or an unbranched or branched C 1 -C 18 alkyl group, C 1 -C 18 alkoxy group, C 1 -C 18 alkenyl group, C 1 -C 18 alkynyl group or C 3 -C 6 cyclic alkyl group, and
wherein the compound of Chemical Formula 1 treats the eye disease in the subject.

2 . The method according to claim 1 , wherein the compound is syringaresinol.

3 . The method according to claim 2 ,
wherein the syringaresinol is administered in a form of an agent, and wherein the agent comprises syringaresinol in an amount of 0.0001-10 wt % based on the total weight of the agent.

4 . The method according to claim 2 , wherein the syringaresinol is included in an extract of one or more selected from flax seed, phellodendri cortex, acanthopanacis cortex, sesame seed and ginseng berry.

5 . The method according to claim 1 , wherein the eye disease comprises an age-related eye disease.

6 . The method according to claim 1 , wherein the eye disease comprises one or more selected from a group consisting of macular degeneration, uveitis, glaucoma, diabetic retinopathy and cataract.

7 . The method according to claim 1 , wherein the method is for increasing SIRT1 expression and mitochondrial synthesis in retinal cells in the subject by activating SIRT1.

8 . The method according to claim 3 ,
wherein the agent is administered in a form of a composition, and the composition comprises 0.001-20 wt % of the agent based on the total weight of the composition.

9 . The method according to claim 8 , wherein the composition is a food composition.

10 . The composition according to claim 8 , wherein the composition is a pharmaceutical composition.

Assignees

• Amorepacific Corp

Inventors

• Kim Byung Gyu
• Jeong Hyun Woo
• Kim Su Kyung
• Cho Si Young
• Park Chan Woong
• Seo Dae Bang
• Kim Wan Gi
• Lee Sang Jun

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P39/02

  Antidotes · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title